Show Summary Details
Page of

VHL and Von Hippel–Lindau Disease 

VHL and Von Hippel–Lindau Disease
VHL and Von Hippel–Lindau Disease

Eamonn R. Maher

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 04 March 2021

Von Hippel–Lindau (VHL) disease is an autosomal dominant familial cancer syndrome caused by germline mutations in the VHL tumor-suppressor gene. VHL is widely expressed in fetal and adult tissues, and the pattern of VHL mRNA expression in the fetal kidney is consistent with a role in normal renal tubular development and differentiation. Mouse models of VHL disease have demonstrated that VHL expression is critical for normal extraembryonic vascular development. pVHL is a component of an E2 ubiquitin ligase complex that regulates expression of the HIF (hypoxia inducible factor) transcription factors such that loss of pVHL is associated with HIF-induced activation of hypoxia response genes (reviewed in Bausch et al 2013).

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.